Diprosalic

Country of origin: Switzerland, Schering-Plough United States of America, Schering-Plough Belgium, Schering-Plough Labo N.V. Belgium
Pharm-Group: Combined products containing glucocorticosteroids

Manufacturers: Schering-Plau (Switzerland), Schering-Plau (United States of America), Schering-Plau (Belgium), Schering-Plau Labo N.V. (Belgium)
International name: Betamethasone + Salicylic acid
Synonyms: Akriderm SK, Belosalik, Betadermik, Betnovate S
Dosage forms: ointment, lotion, suspension
Composition: Active substances - betamethasone dipropionate and salicylic acid.
Indications for use: Dermatoses (subacute, chronic), sensitive to external therapy with glucocorticoids and accompanied by hyperkeratosis: psoriasis, lichen planus, eczema, dyshydratic dermatitis, atopic dermatitis (neurodermatitis), ichthyosis and ichthyosoform changes.
Contraindications: Hypersensitivity, skin tuberculosis, viral skin infections, vaccination, perioral dermatitis, rosacea. Use during pregnancy and breastfeeding: Possible during pregnancy if the expected effect of therapy exceeds the potential risk to the fetus (short time and on small surfaces). Possible during breastfeeding (short time and on small surfaces, excluding the skin of the breast before feeding).
Side effects: Local - burning sensation, itching, folliculitis, acne, stretch marks, skin atrophy, depigmentation, hypertrichosis. Systemic (with long-term use over large areas of skin, when using occlusive dressings) - symptoms of overdose of glucocorticoids (growth retardation, reversible suppression of ACTH release, Cushing's syndrome, increased intracranial pressure after treatment, hyperglycemia) or salicylates (pallor, fatigue, drowsiness, hyperventilation lungs, tachypnea, nausea, vomiting, hearing impairment, confusion, etc.).
Interaction: No data available.
Overdose: Symptoms: inhibition of the function of the pituitary-adrenal system, leading to secondary adrenal insufficiency and symptoms of hypercortisolism, including Cushing's disease. Treatment: systematic therapy.
Special instructions: The use of the drug in children under 12 years of age is carried out under the supervision of the attending physician. Long-term use on the face is not recommended. The drug should not be applied to the skin near the eyes. Use in the anogenital area should be avoided. Caution should be exercised in patients with impaired liver function.
Literature:

1. Encyclopedia of Medicines, 2004.
2. Encyclopedia of Medicines, 2003.